Business Description
Read-Gene SA
ISIN : PLRADGN00014
Total Employee Number:
22Description
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.67 | |||||
Equity-to-Asset | 0.31 | |||||
Debt-to-Equity | 1.8 | |||||
Debt-to-EBITDA | 2.99 | |||||
Interest Coverage | 6.77 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 5.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 29.2 | |||||
3-Year EBITDA Growth Rate | 6.5 | |||||
3-Year EPS without NRI Growth Rate | -61.8 | |||||
3-Year Book Growth Rate | -17.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.41 | |||||
9-Day RSI | 53.12 | |||||
14-Day RSI | 50.83 | |||||
3-1 Month Momentum % | -3.49 | |||||
6-1 Month Momentum % | -15.59 | |||||
12-1 Month Momentum % | -4.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.41 | |||||
Quick Ratio | 4.38 | |||||
Cash Ratio | 2.71 | |||||
Days Inventory | 14.81 | |||||
Days Sales Outstanding | 60.45 | |||||
Days Payable | 401.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -0.68 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.23 | |||||
Operating Margin % | 14.14 | |||||
Net Margin % | 12.51 | |||||
EBITDA Margin % | 17.48 | |||||
FCF Margin % | -2.94 | |||||
OCF Margin % | -0.6 | |||||
ROE % | 78.15 | |||||
ROA % | 14.4 | |||||
ROIC % | 24.93 | |||||
3-Year ROIIC % | 1.9 | |||||
ROC (Joel Greenblatt) % | 36.42 | |||||
ROCE % | 21.18 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 28.76 | |||||
PE Ratio without NRI | 29.28 | |||||
Price-to-Owner-Earnings | 24.92 | |||||
PS Ratio | 3.6 | |||||
PB Ratio | 12.43 | |||||
Price-to-Tangible-Book | 12.46 | |||||
EV-to-EBIT | 26.05 | |||||
EV-to-EBITDA | 21.74 | |||||
EV-to-Revenue | 3.8 | |||||
EV-to-FCF | -129.41 | |||||
Price-to-GF-Value | 0.76 | |||||
Price-to-Projected-FCF | 6 | |||||
Price-to-Median-PS-Value | 0.89 | |||||
Price-to-Graham-Number | 4.02 | |||||
Earnings Yield (Greenblatt) % | 3.84 | |||||
FCF Yield % | -0.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Read-Gene SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil zł) | 15.902 | ||
| EPS (TTM) (zł) | 0.169 | ||
| Beta | -0.1959 | ||
| 3-Year Sharpe Ratio | 0.44 | ||
| 3-Year Sortino Ratio | 1.01 | ||
| Volatility % | 29 | ||
| 14-Day RSI | 50.83 | ||
| 14-Day ATR (zł) | 0.12759 | ||
| 20-Day SMA (zł) | 4.7735 | ||
| 12-1 Month Momentum % | -4.6 | ||
| 52-Week Range (zł) | 4.57 - 6.9 | ||
| Shares Outstanding (Mil) | 11.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Read-Gene SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Read-Gene SA Stock Events
| Event | Date | Price (zł) | ||
|---|---|---|---|---|
| No Event Data | ||||
Read-Gene SA Frequently Asked Questions
What is Read-Gene SA(WAR:RDG)'s stock price today?
The current price of WAR:RDG is zł4.86. The 52 week high of WAR:RDG is zł6.90 and 52 week low is zł4.57.
When is next earnings date of Read-Gene SA(WAR:RDG)?
The next earnings date of Read-Gene SA(WAR:RDG) is .
Does Read-Gene SA(WAR:RDG) pay dividends? If so, how much?
Read-Gene SA(WAR:RDG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Read-Gene SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers